Jose L. Lopez-Ribot to Candida
                            
                            
                                This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about Candida.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            6.482
         
        
        
     
 
    
        
        - 
            Romo JA, Lopez-Ribot JL. Candidalysin: An unlikely aide for fungal gut commensalism. Cell Host Microbe. 2024 May 08; 32(5):625-626.
            
            
                Score: 0.943
             
- 
            Ramage G, Borghi E, Rodrigues CF, Kean R, Williams C, Lopez-Ribot J. Our current clinical understanding of Candida biofilms: where are we two decades on? APMIS. 2023 Nov; 131(11):636-653.
            
            
                Score: 0.873
             
- 
            Ajetunmobi OH, Wall G, Bonifacio BV, Montelongo-Jauregui D, Lopez-Ribot JL. A 384-Well Microtiter Plate Model for Candida Biofilm Formation and Its Application to High-Throughput Screening. Methods Mol Biol. 2023; 2658:53-64.
            
            
                Score: 0.859
             
- 
            Wall G, Chen E, Hull MV, Lopez-Ribot JL. Screening the CALIBR ReFRAME Library in Search for Inhibitors of Candida auris Biofilm Formation. Front Cell Infect Microbiol. 2020; 10:597931.
            
            
                Score: 0.742
             
- 
            Lara HH, Ixtepan-Turrent L, Jose Yacaman M, Lopez-Ribot J. Inhibition of Candida auris Biofilm Formation on Medical and Environmental Surfaces by Silver Nanoparticles. ACS Appl Mater Interfaces. 2020 May 13; 12(19):21183-21191.
            
            
                Score: 0.699
             
- 
            Pierce CG, Srinivasan A, Ramasubramanian AK, L?pez-Ribot JL. From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. Microbiol Spectr. 2015 Jun; 3(3).
            
            
                Score: 0.508
             
- 
            Ramage G, Mart?nez JP, L?pez-Ribot JL. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 2006 Nov; 6(7):979-86.
            
            
                Score: 0.280
             
- 
            Ramage G, Saville SP, Thomas DP, L?pez-Ribot JL. Candida biofilms: an update. Eukaryot Cell. 2005 Apr; 4(4):633-8.
            
            
                Score: 0.251
             
- 
            Ajetunmobi OH, Chaturvedi AK, Badali H, Vaccaro A, Najvar L, Wormley FL, Wiederhold NP, Patterson TF, Lopez-Ribot JL. Screening the medicine for malaria venture's Pandemic Response Box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation. APMIS. 2023 Nov; 131(11):613-625.
            
            
                Score: 0.222
             
- 
            Ramage G, Vande Walle K, Wickes BL, L?pez-Ribot JL. Biofilm formation by Candida dubliniensis. J Clin Microbiol. 2001 Sep; 39(9):3234-40.
            
            
                Score: 0.196
             
- 
            Banerjee M, Lazzell AL, Romo JA, Lopez-Ribot JL, Kadosh D. Filamentation Is Associated with Reduced Pathogenicity of Multiple Non-albicans Candida Species. mSphere. 2019 10 16; 4(5).
            
            
                Score: 0.172
             
- 
            Dekkerov? J, Lopez-Ribot JL, Bujd?kov? H. Activity of anti-CR3-RP polyclonal antibody against biofilms formed by Candida auris, a multidrug-resistant emerging fungal pathogen. Eur J Clin Microbiol Infect Dis. 2019 Jan; 38(1):101-108.
            
            
                Score: 0.160
             
- 
            Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis. 2006 Apr 01; 193(7):1014-22.
            
            
                Score: 0.067
             
- 
            S?nchez-Vargas LO, Ortiz-L?pez NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gait?n-Cepeda LA, Quind?s G. Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico. J Clin Microbiol. 2005 Aug; 43(8):4159-62.
            
            
                Score: 0.064
             
- 
            S?nchez-Vargas LO, Ortiz-L?pez NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gait?n-Cepeda LA, Quind?s G. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol. 2005 Jun; 22(2):83-92.
            
            
                Score: 0.063
             
- 
            Viudes A, Pem?n J, Cant?n E, Ubeda P, L?pez-Ribot JL, Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis. 2002 Nov; 21(11):767-74.
            
            
                Score: 0.053
             
- 
            Martinez M, L?pez-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol. 2002 Sep; 40(9):3135-9.
            
            
                Score: 0.052
             
- 
            Perea S, L?pez-Ribot JL, Wickes BL, Kirkpatrick WR, Dib OP, Bachmann SP, Keller SM, Martinez M, Patterson TF. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002 Jun; 46(6):1695-703.
            
            
                Score: 0.052
             
- 
            Viudes A, Pem?n J, Cant?n E, Salavert M, Ubeda P, L?pez-Ribot JL, Gobernado M. Two cases of fungemia due to Candida lusitaniae and a literature review. Eur J Clin Microbiol Infect Dis. 2002 Apr; 21(4):294-9.
            
            
                Score: 0.051
             
- 
            Redding SW, Bailey CW, Lopez-Ribot JL, Kirkpatrick WR, Fothergill AW, Rinaldi MG, Patterson TF. Candida dubliniensis in radiation-induced oropharyngeal candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun; 91(6):659-62.
            
            
                Score: 0.048
             
- 
            Kirkpatrick WR, Lopez-Ribot JL, McAtee RK, Patterson TF. Growth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions. J Clin Microbiol. 2000 Feb; 38(2):902-4.
            
            
                Score: 0.044
             
- 
            Redding SW, Zellars RC, Kirkpatrick WR, McAtee RK, Caceres MA, Fothergill AW, Lopez-Ribot JL, Bailey CW, Rinaldi MG, Patterson TF. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol. 1999 Dec; 37(12):3896-900.
            
            
                Score: 0.043
             
- 
            Kirkpatrick WR, Revankar SG, Mcatee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, Sanche SE, Cantu RA, Rinaldi MG, Patterson TF. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol. 1998 Oct; 36(10):3007-12.
            
            
                Score: 0.040